K034011 1 of 2

510(k) Summary Statement For the GeminiTM G Surgical Laser System & Accessories

General Information

- A. Trade Name GeminiTM Series Surgical Laser System
- B. Common Name Laser Instrument, Surgical, Powered
- C. Establishment Registration Number

2937094

D. Manufacturer's Identification

Laserscope 3070 Orchard Drive San Jose, CA 95134-2011 (800) 243-9384-ext. 6795 (408) 943-9630 FAX

Official Correspondent
Paul Hardiman
Manager, Regulatory Affairs/Clinical Affairs

E. Device Classification

The Gemini Series Surgical Laser System has been specifically classified as a Class II medical device by the OB/GYN, General Plastic Surgery, and ENT Device Advisory Panels.

F. Performance Standards

The Gemini Series Surgical Laser System conforms with federal regulations and the performance standards 21 CFR 1040.10 and 1040.11 for medical laser systems.

- G. Predicate Devices:
 - Laserscope Lyra[™] G Laser System and Accessories
 - AURA i™ Surgical Laser System & Accessories
 - Laserscope LyraTM Laser System and Accessories

K034011 2 of 2

H. Product Description:

The Laserscope GeminiTM Surgical Laser System and Accessories consists of four major subsystems:

- The Optical and Laser resonator System
- · The Electronics and Electrical System
- Operator Interface
- A variety of Delivery Devices and Accessories
- A Cooling Sub-system

Indications For Use:

The Laserscope GeminiTM Laser System & Accessories is indicated for:

KTP/532 Applications:

Dermatology: To treat moderate inflamatory acne vulgaris;

ND:YAG/1064 Applications:

Dermatology: For use in the Dermatological Applications for the treatment of facial wrinkles. It is also intended to effect stable long-term, or permanent hair reduction in skin types I – VI through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as a long-term, stable, reduction in the number of hairs re-growing after a treatment regimen.

Rationale for Substantial Equivalence

The Laserscope Gemini Surgical Laser System and Accessories share the same indications for use, similar design features, functional features, and therefore are substantially equivalent to: the Laserscope Lyra G Surgical Laser System and Accessories; the Laserscope Aura "DL" Series Surgical Laser Systems (KTP/532, KTP/YAGTM and Nd:YAG/1064 Configurations);and, the Laserscope Lyra Laser System and Accessories. Details are provided in the Substantial Equivalence Section of this submission.



MAR 3 0 2004

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Paul H. Hardiman Manager, Regulatory Affairs Laserscope 3070 Orchard Drive San Jose, California 95134

Re: K034011

Trade/Device Name: GEMINI™ Surgical Laser System & Accessories

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and

plastic surgery and in dermatology

Regulatory Class: II Product Code: GEX

Dated: December 22, 2003 Received: December 31, 2003

Dear Mr. Hardiman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

Page 1

C46/L	61
STUCKI	Number.

K034011

Device Name:

GEMINI™ SURGICAL LASER SYSTEM & ACCESSORIES

INTENDED USE:

The Laserscope GeminiTM Laser System & Accessories is indicated for:

KTP/532 Applications:

Dermatology: To treat moderate inflammatory Acne vulgaris.

ND:YAG/1064 Applications:

Dermatology: For use in the Dermatological Applications for the treatment of facial wrinkles. It is also intended to effect stable long-term, or permanent hair reduction in skin types I - VI through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as a long-term, stable, reduction in the number of hairs re-growing after a treatment regimen.

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use:

Over The-Counter-Use

(per 21 CFR 801.109)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE)

Division of General, Restorative,

and Neurological Devices

510(k) Number K 034011